This site is intended for health professionals only

Priority review for new pain drug


Two leading pharmaceutical companies have said that US health regulators have granted a priority review of their experimental pain drug Acurox.

The Food and Drug Administration (FDA) has set a target date of June 30 to review whether the new drug Acurox, which has been created by Acura Pharmaceuticals and King Pharmaceuticals, will be approved.

Under the Prescription Drug User Fee Act (PDUFA) the FDA has made the review of the drug, which includes the powerful oxycodone pain medicine, a top priority – meaning it now has just six months to make a decision.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in clinical care at events delivered by renowned experts from CofE

The review is granted for products that are considered to be more advanced over existing therapies and Acurox, which contains components designed to thwart prescription drug abuse, common with opioid pain drugs, is believed to be one step ahead of existing pain relief alternatives.

Tennessee based King announced in October last year that it was signing a deal to use Acura’s Aversion abuse-deterrent technology. It has now applied this technology to three opioid drugs, including Acurox tablets.

Copyright Press Association 2009

Food and Drug Administration

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine